Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00.

Vaxcyte Trading Up 0.5 %

Shares of NASDAQ:PCVX opened at $86.21 on Friday. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06. The company has a market cap of $10.74 billion, a price-to-earnings ratio of -18.74 and a beta of 0.94. The company has a 50-day moving average price of $99.26 and a 200-day moving average price of $92.03.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Riverview Trust Co bought a new position in shares of Vaxcyte during the third quarter valued at approximately $27,000. Blue Trust Inc. increased its position in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares in the last quarter. Fifth Third Bancorp purchased a new position in Vaxcyte during the second quarter valued at $35,000. Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after acquiring an additional 635 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte in the third quarter worth $92,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Leerink Partners upped their price target on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday. They issued a “buy” rating and a $135.00 price target on the stock. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.